Device Trial Radar · NCT06645236
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Dec 22, 2023
Primary completion
Oct 31, 2030
Study completion Oct 31, 2030
Sponsor
- Lead sponsor
- QIAGEN Gaithersburg, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of the Phase 3 Amgen Study 20210081 will serve as the basis for establishing the clinical performance of the therascreen® KRAS RGQ PCR Kit as a companion diagnostic (CDx) for the identification of patients with metastatic colorectal cancer, who may benefit from treatment with sotorasib.
Conditions
- Metastatic Colorectal Cancer (mCRC)
Interventions
therascreen® KRAS RGQ PCR KitDevice
The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection of KRAS G12C mutation statusTime frame: 6 years; due to end 2030
- Progression Free Survival (PFS)Time frame: 6 years; due to end 2030
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QIAGEN Gaithersburg, Inc
Manchester, Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.